Akebia Therapeutics - AKBA Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AKBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View AKBA analyst ratings or view top-rated stocks.

6 brokers have issued 12 month target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $1.25 to $2.00. On average, they predict the company's share price to reach $1.75 in the next year. This suggests a possible upside of 446.9% from the stock's current price.
View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts.

Akebia Therapeutics' stock was trading at $2.26 at the start of the year. Since then, AKBA shares have decreased by 85.8% and is now trading at $0.32.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AKBA earnings forecast.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.54. The biopharmaceutical company had revenue of $126.76 million for the quarter, compared to analysts' expectations of $49.10 million. Akebia Therapeutics had a negative net margin of 55.04% and a negative trailing twelve-month return on equity of 197.12%. During the same quarter last year, the company posted ($0.51) EPS.

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (2.91%), Federated Hermes Inc. (1.08%), Renaissance Technologies LLC (0.81%), AQR Capital Management LLC (0.47%), FMR LLC (0.34%) and State Street Corp (0.31%). Insiders that own company stock include David A Spellman, Dell Faulkingham, Jason Amello, John P Butler, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends.

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKBA stock can currently be purchased for approximately $0.32.

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $58.83 million and generates $213.58 million in revenue each year. The biopharmaceutical company earns $-282,840,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

The company employs 426 workers across the globe.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.